Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Standard warfarin dose in a patient with the CYP2C93/3 genotype leads to hematuria.

Clinica chimica acta; international journal of clinical chemistry - 6 Sept 2010

Goto Toshiharu, Miura Masatomo, Murata Atsunobu, Terata Ken, Uno Tsukasa, Yamamoto Koujirou, Abe Yoshihisa

Abstract excerpt

BACKGROUND: Patients with certain CYP2C9 genetic variants have increased sensitivity to warfarin and are at increased risk of over-coagulation with standard warfarin dose. We report over-anticoagulation and hematuria manifest as a slow increase in the international normalized ratio (INR) due to warfarin treatment in a patient with the CYP2C9*3/*3 allele. CASE: A 58-y-old man with paroxysmal atrial fibrillation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Atrial Fibrillation

Share to Cytochrome P-450 CYP2C9

Share to VKORC1 gene

Share to Genotype

Share to Hematuria

Share to Warfarin

Source

Identifiers

PMID: 20420818
DOI: 10.1016/j.cca.2010.04.014

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Standard warfarin dose in a patient with the CYP2C9*3/*3 genotype leads to hematuria.PMID 20420818Read ↗

Warfarin therapy in a patient homozygous for the CYP2C9 3 allele.Semantic proximity Read ↗

Low dose requirement for warfarin treatment in a patient with CYP2C9*3/*13 genotype.Semantic proximity Read ↗

Warfarin dose adjustments based on CYP2C9 genetic polymorphisms.Semantic proximity Read ↗

Several-fold increase in risk of overanticoagulation by CYP2C9 mutations.Semantic proximity Read ↗

Genetic association between sensitivity to warfarin and expression of CYP2C9*3.Semantic proximity Read ↗

Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response.Semantic proximity Read ↗

Effect of polymorphisms in the cytochrome P450 CYP2C9 gene on warfarin anticoagulation.Semantic proximity Read ↗

Pharmacogenetics of warfarin elimination and its clinical implications.Semantic proximity Read ↗

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.Semantic proximity Read ↗

Severely diminished response to vitamin K-treatment for self-inflicted warfarin intoxication in a patient genotyped as CYP2C9*3*3.Semantic proximity Read ↗

CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.Semantic proximity Read ↗

A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.